Technical analysis of Elutia Inc (ELUT): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction.
Price Performance
| 1 month | -10.99% |
| 3 months | -23.58% |
| Year-to-date | +16.93% |
| 1 year | -28.32% |
| 3 years | -34.68% |
| 5 years | -90.18% |
52-Week Range
| 52-week High | $1.39 |
| 52-week Low | $0.50 |
| Avg Volume (90d) | 84K |
Technical Indicators
| SMA 50 | $0.89 |
| SMA 200 | $0.95 |
| Beta | 0.71 |
| 30-day Volatility (annualised) | 63.5% |
| Price vs SMA 50 | -9.2% |
| Price vs SMA 200 | -14.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $0.91 | |
| 2025-11 | $0.61 | -32.7% |
| 2025-12 | $0.69 | +13.2% |
| 2026-01 | $1.05 | +51.6% |
| 2026-02 | $1.15 | +9.5% |
| 2026-03 | $1.05 | -8.7% |
| 2026-04 | $1.02 | -2.9% |
| 2026-05 | $1.16 | +13.7% |
| 2026-06 | $0.98 | -15.6% |
| 2026-07 | $0.86 | -12.5% |
| 2026-08 | $0.86 | +0.9% |
| 2026-09 | $0.81 | -6.3% |
Price
| Price | $0.81 |
| Market Cap | $36M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 0.60 |
| Price / Book | 2.18 |
| EV / EBITDA | -1.13 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.69 |
| Current Ratio | 1.77 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -3.65 |